TDN345 is a antagonist of Ca2+, for the treatment of vascular and senile dementia including Alzheimer's disease.

In the time-course study,TDN-345 treatment with 10 μM significantly increases the intracellular NGF content. TDN-345 induces NGF synthesis/secretion at the concentrations of 0.1 μM; statistically significant at 1 μM(ED50 of 0.88 μM)[1].

When administered orally twice TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score, 60 min before ischemia and 90 min after recirculation. Additionally, In SHRSP, TDN-345 decreases the mortality and recurrence of stroke [2].

134069-68-4

C28H34F2N2O2

468.58

TDN345

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years